Italia markets closed

Valneva SE (VLA.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
10,15-0,20 (-1,98%)
Alla chiusura: 05:35PM CEST
Schermo intero
Chiusura precedente10,36
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno10,12 - 10,67
Intervallo di 52 settimane7,26 - 29,70
Media Volume811.099
Beta (5 anni mensile)0,93
Rapporto PE (ttm)N/D
EPS (ttm)-0,71
Prossima data utili10 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,57
  • GlobeNewswire

    Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

    Saint-Herblain (France), August 15, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an At-the-Market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0 million of American Depositar

  • GlobeNewswire

    Valneva Reports H1 2022 Results and Provides Corporate Updates

    Excellent progress on late-stage clinical programs Lyme Disease Vaccine Candidate VLA15 Phase 3 study initiated in August 20221Further positive Phase 2 results reported, including first pediatric data2 Single-Shot Chikungunya Vaccine Candidate VLA1553 Initiation of rolling submission for Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) imminentFinal positive pivotal Phase 3 results reported3Final positive lot-to-lot consistency Phase 3 results reported4 Four m

  • GlobeNewswire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S. New York & Saint-Herblain (France), August 8, 2022 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate,